Nanomedicine and personalised medicine: understanding the personalisation of health care in the molecular era

Noury, Mathieu; López, José Julián

doi:10.1111/1467-9566.12502

Cited by 7 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The debates surrounding the use of NMs in medicine are part of a broader framework, that of the controversies over nanotechnologies (36). It seems important to assess acceptability and to implement measures to raise awareness of the applications, uses and benefits of these technologies (37).…”

Section: Societal Topicsmentioning

confidence: 99%

Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products

Oualikene-Gonin

Sautou²,

Ezan³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

Nanomaterials are present in a wide variety of health products, drugs and medical devices and their use is constantly increasing, varying in terms of diversity and quantity. The topic is vast because it covers nanodrugs, but also excipients (that includes varying proportions of NMs) and medical devices (with intended or not-intended (by-products of wear) nanoparticles). Although researchers in the field of nanomedicines in clinical research and industry push for clearer definitions and relevant regulations, the endeavor is challenging due to the enormous diversity of NMs in use and their specific properties. In addition, regulatory hurdles and discrepancies are often cited as obstacles to the clinical development of these innovative products. The scientific council of the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) undertook a multidisciplinary analysis encompassing fundamental, environmental and societal dimensions with the aim of identifying topics of interest for regulatory assessment and surveillance. This analysis allowed for proposing some recommendations for approximation and harmonization of international regulatory practices for the assessment of the risk/benefit balance of these products, considering as well the public expectations as regards efficacy and safety of nanomaterials used in Health products, in terms of human and environmental health.

show abstract

Section: Societal Topicsmentioning

confidence: 99%

Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products

Oualikene-Gonin

Sautou²,

Ezan³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Personalized medicine is one of major expectations of nanomedicine, enabling diagnostics and therapeutics to target individual needs and developing a truly "patient-friendly" medical approach [62]. At the same time, the rapidly evolving field of molecular imaging promises improvements in patient screening and early diagnosis [63,64].…”

Section: Theranostic Use Of Ferritinmentioning

confidence: 99%

Ferritin: A Platform for MRI Contrast Agents Delivery

et al. 2019

View full text Add to dashboard Cite

The search for high relaxivities and increased specificity continues to be central to the development of paramagnetic contrast agents for magnetic resonance imaging (MRI). Ferritin, due to its unique surface properties, architecture, and biocompatibility, has emerged as a natural nanocage that can potentially help to reach both these goals. This review aims to highlight recent advances in the use of ferritin as a nanoplatform for the delivery of metal-based MRI contrast agents (containing Gd3+, Mn2+, or Fe2O3) alone or in combination with active molecules used for therapeutic purposes. The collected results unequivocally show that the use of ferritin for contrast agent delivery leads to more accurate imaging of cancer cells and a significantly improved targeted therapy.

show abstract

“…Personalised healthcare, just like digital health technology, needs personal health data from the individual patient in order to perform health services (cf. Noury and López 2017 ). Thus, the patient is expected to provide personal data to the digital health technologies (cf.…”

Section: Introductionmentioning

confidence: 99%

The making of a professional digital caregiver: personalisation and friendliness as practices of humanisation

Hallqvist

2021

Med Humanities

View full text Add to dashboard Cite

The aim of this paper is to explore how a digital caregiver, developed within a Swedish interdisciplinary research project, is humanised through health-enhancing practices of personalisation and friendliness. The digital caregiver is developed for being used in older patients’ homes to enhance their health. The paper explores how the participants (researchers and user study participants) of the research project navigate through the humanisation of technology in relation to practices of personalisation and friendliness. The participants were involved in a balancing act between making the digital caregiver person-like and friend-like enough to ensure the health of the patient. Simultaneously, trying to make the patients feel like as if they were interacting with someone rather than something—while at the same time not making the digital caregiver seem like a real person or a real friend. This illustrates the participants’ discursive negotiations of the degree of humanisation the digital caregiver needs in order to promote the health of the patient. A discursive conflict was identified between a patient discourse of self-determination versus a healthcare professional discourse of authority and medical responsibility: whether the digital caregiver should follow the patient’s health-related preferences or follow the healthcare professionals’ health rules. Hence, a possible conflict between the patient and the digital caregiver might arise due to different understandings of friendliness and health; between friendliness (humanisation) as a health-enhancing practice governed by the patient or by the healthcare professionals (healthcare professionalism).

show abstract

Nanomedicine and personalised medicine: understanding the personalisation of health care in the molecular era

Cited by 7 publications

References 88 publications

Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products

Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products

Ferritin: A Platform for MRI Contrast Agents Delivery

The making of a professional digital caregiver: personalisation and friendliness as practices of humanisation

Contact Info

Product

Resources

About